Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Stock Information for PharmaCyte Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PharmaCyte Biotech Inc.

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.